Advertisement
U.S. markets closed

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.9900-0.0400 (-0.99%)
At close: 04:00PM EST
3.9700 -0.02 (-0.50%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.0300
Open4.0400
Bid3.7500 x 800
Ask3.8900 x 900
Day's Range3.7600 - 4.0800
52 Week Range2.6050 - 9.0800
Volume1,260,939
Avg. Volume1,442,216
Market Cap583.434M
Beta (5Y Monthly)1.27
PE Ratio (TTM)N/A
EPS (TTM)-1.5500
Earnings DateMay 01, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADPT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adaptive Biotechnologies Corpor
    Analyst Report: Intellia Therapeutics, Inc.Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

    SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA. Adaptive Biotechnologies’ management is scheduled to present on Monday, March 4th at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern

  • Insider Monkey

    Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript

    Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript February 14, 2024 Adaptive Biotechnologies Corporation beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.32. Adaptive Biotechnologies Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing […]

  • Thomson Reuters StreetEvents

    Q4 2023 Adaptive Biotechnologies Corp Earnings Call

    Q4 2023 Adaptive Biotechnologies Corp Earnings Call